Arabic Arabic English English French French German German

In Vitro and In Vivo BE Approaches: Challenges and Opportunities – Session 3A

Presentations and a panel consider the utility of in vitro characterization and modeling approaches to support biowaivers for certain non-Q1/Q2 formulations of prospective generic products. Presentations include, “Mechanistic Assessment of Excipient Changes for Biopharmaceutics Classification System (BCS) 1 Class and 3 Drug Products” and “BCS Class 3 Compounds: In Vivo Experience with Non-Q1/Q2 Formulations.”
Learn more at:
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  

Upcoming Training –   
SBIA Listserv –
SBIA 2021 Playlist –
SBIA LinkedIn –  
SBIA Training Resources –  
Twitter –  
Email –  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Should I have my AstraZeneca booster shot at 8 weeks rather than 12? Here’s the evidence so you can decide

Next Post

Stay safe from COVID-19: Get a COVID-19 shot

Related Posts